ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Engineering Approaches To Respiratory Drug Delivery

  Explore the material and performance properties of spray-dried and jet-milled mannitol for respiratory delivery of crystalline mannitol.

• A Solvent-Free, Fusion-Based ASD Manufacturing Process

  Explore a solvent-free alternative for the production of amorphous solid dispersions (ASDs) that not only improves manufacturability but also reduces the carbon footprint of ASD manufacturing.

• Nanoparticle Engineering Addresses The Challenge Of Poor Aqueous Solubility

  As pharma companies aim to overcome development obstacles, it is important to incorporate GMP expertise alongside novel technologies that can enhance the properties of APIs and dosage forms.

• Container Closure Integrity: A Risk-Based Approach

  Container closure integrity is essential to protecting drug product and satisfying regulatory agencies. A risk-based approach enables creation of a robust data file for timely approval of regulatory applications.

• The Future Of Pharma Packaging Trends, Technologies, And Patient-Centric Solutions

  Pharmaceutical packaging must evolve alongside drug development to ensure stability, safety, and regulatory adherence, utilizing innovative designs to improve therapeutic outcomes and patient accessibility.

• Leveraging Integration At Each Phase Of A Drug Delivery System Project

  By forging deeper partnerships with customers, the full depth and breadth of our knowledge, experience and competencies can bring benefits at multiple levels. See how an integrated offering helps at each phase of a drug delivery system project.

• Managing Poor Solubility With Cutting-Edge Formulation Approaches

  An increasing number of poorly soluble APIs are the cornerstone of cutting-edge therapies, necessitating equally complex formulation technologies to maintain or improve solubility and, ultimately, bioavailability.

• Why It Is Never Too Early To Consider Tungsten Interactions

  A key challenge to sensitive biotechnological or biologic drugs, especially proteins, is the potential presence of tungsten and tungsten oxides from the syringe forming process.

• USP <382>: Think Systems, Not Components

  This blog focuses on the application of USP <382> prescribed testing to cartridges and syringes from a mechanical testing perspective.

• Successful Industrialization Requires Solid Foundations

  Learn how choosing the appropriate quality of containment systems from the outset is critical to the successful industrialisation of an injectable drug product and review some of the associated challenges.